

Index

Numbers in **Bold** indicate page where chemical formula is shown.

A

Acetylcholine, 162
 glucose uptake *S. mansoni*, 196
 motility in flatworms, 178
 Acetylcholine receptors, 157–62
 genes in nematodes, 182
 neurotoxins in nematodes, 158–60
 nicotinic anthelmintics, **160**, 159–62
S. mansoni tegument, 198
 Acetylcholinesterase
 inhibitor (metrifonate), 197–9
 in *S. hematobium*, 196–8
 Adenosine kinase *T. gondii*, 111, 114–5
 Adenosine P₂ transporters, 111–2
 Adenylyl cyclase, 41–4, 170, 176, 183
 Albendazole, **171**, 173
 Alcohol dehydrogenase
 NADP, 133, NAD, 133, 146–7
 Allium sativum & amebiasis, 149
 Allopurinol, **112**, 12–3, 112–4
 Anaerobic mitochondrial enzymes
A. suum, 48–51
F. hepatica, 46–9
H. diminuta, 46, 51
Ancylostoma duodenale, 159
 Antifolate antimalarials, 77–82
 Antigenic variation in trypanosomes, 117
 lipid synthesis inhibitors, 118
 myristate analog inhibitors, 118
 Antimony potassium tartrate (*see* potassium antimony tartrate)
 Antisense oligodeoxynucleotides, 84–5
 Arginine, *Giardia* energy source, 134–5

Artemisinin, antimalarial, **75**, 74–5
Ascaris
 anaerobic metabolism, 46–50
 antinematodal agents, 45, 50–54, 159–64,
 170–4
 fumarate reductase, 48–9, 51–4
 GABA-Cl⁻ channels, 163–4, 182
 glutamate-gated channels, 164–8
 life cycle, 34–5
 malic dehydrogenase
 mebendazole inhibition, 53–4
 microtubules & benzimidazoles,
 170–4
 neuromuscular system, 156–7
 neuropeptides, 174–5
 nicotinic receptors, 157–9
 PFK, antimonial inhibition, 45
 pyruvate dehydrogenase complex (PDC),
 49–50
 serotonin effects, 169–70

B

Benzimidazoles, **171**, **207**, 53, 164
 antimicrotubular effect, 170–2, 207
 resistance to, 173–4
 Bephenium, **160**, 159
 Bioamine receptors nematodes, 169–70
 Bithionol, **53**, 52–3, 207
 2-Br-LSD (BOL), **42**, 42–3, 183
Brugia malayi, 11, 24, 215
 diethylcarbamazine, 162
 Wolbachia endobacteria, 216–7
Brugia pahangi, inhibition of PFK, 45

222 Index

C*Caenorhabditis elegans*

- chloride channels, 166–7
- gene silencing (RNAi), 215
- genome, 24–5, 158–9, 165–6, 181–3
- levamisole resistance, 160–1
- serotonin receptors, 169–70, 183

Carbachol, 21, 178

Chloroquine, **61**, (antimalarial), 61–64

- resistance to, 70–1
- uptake of, 72–3

Chloroguanil (antimalarial), 81

Combinatorial chemistry, 14–16, 68

Crithidia fasciculata

- trypanothione reductase, 93
- trypanredoxin, 218

Cyclic-3',5'-AMP (cAMP), 41–3, 169

DDesaspidin, **52**, (anticestodal), 51Dichlorophen, **52**, (anticestodal), 51Dichlorvos, **197**

- S. hematobium*, 198

Diethylcarbamazine, **162**, 162

Dihydrofolate reductase-thymidylate synthase, 80–2

- antimalarial target, 80–2
- antisense deoxynucleotides, 84–5
- in Leishmania, 116

Dihydropteroate synthase (DHPS), 4

- inhibition by sulfonamides, 77–9

Dipyridamole, **111**, 111–2Dithiazanine, **51**, against *Ascaris*, 51

DNA microarrays, 216

DNA recombinant technology, 22–7

Doxycycline synergism with ivermectin, 216–7

Drug design, 3, 13, 93, 106

Dyneins in *S. mansoni*, 206–7**E**Eflornithine (DMFO), **99**, 99–101, 219

Ehrlich, Paul, 2–4, 76, 106

Embsden-Meyerhof pathway, **38**, 7, 37, 131–2*Entamoeba histolytica*

- biology and life cycle, 130
- carbohydrate metabolism, 131–3
 - PP₁ enzymes, 131–4, 145
 - alcohol dehydrogenase as a target, 133, 146–7
- cysteine proteinases, 148–9,
 - PFOR, 133–4, 137–8, 142–8

Enterobius vermicularis

- nicotinic anthelmintics, 160, 173,

F

Farnesylation, 29, 119

Fasciola hepatica

- fumarate reductase, 49
- life cycle, 34
- neuromuscular system, 175, 178
- neuropeptides, 180
- PFK, 40–1
- praziquantel effects on, 204
- serotonin & motility, 176–7
- serotonin & glycolysis, 41–3
- signal transduction, 43–4
- tegument, 189, 194
 - triclabendazole effect, 207

Fatty acids in *T. brucei*, 117–8Fenbendazole, **171**, 173,

Ferredoxin, 133–5, 137–42, 218

Formycin, **113**

- purine salvage, 110, 113–4

Fumarate reductase in helminths, 48–9

- inhibitors, 51–3

G

G-proteins, helminths, 119, 169–70

- cloning from *S. mansoni*, 43

GABA (γ -amino butyric acid), 157, 163–4, 182

GAPDH, 105–6, 193

G. lamblia (see *Giardia intestinalis*)

Gene silencing (see RNAi), 215–6

Genomics, 27–8

- C. elegans*, 25, 181–2
- parasitic helminths, 24–5
- P. falciparum*, 26–7
- structural, 27–8
- trypanosomatids, 25–6

Giardia intestinalis

- energy metabolism, 21–2, 134–5
- arginine metabolism, 135
- inhibitors of excystation, 149–50
- life cycle, 130
- metronidazole, 141–3, 148
- PFOR, 138, 148

Gilman, Alfred G., 43

Glucose transporters

- S. mansoni*, 36–7, 194–5
- T. brucei*, 104

Glutamate-gated Cl⁻ channels, 164

- ivermectin, 165–8

Glutamate receptors, nematodes,
 164–8

Glutathione reductase, malaria, 217

Glutathione S-transferase, 193

α -glycerophosphate oxidase inhibition by
 SHAM, 105

Glycerophosphate oxidase in *T. brucei*,
 103

Glycolysis
Ascaris & tapeworms, 46–50
E. histolytica, 131–4
Giardia, 134–5
S. mansoni, 35–45
 trypanosomatids, 101–6

Glycolytic pathway, **38**

H

Haemonchus contortus
 benzimidazole resistance, 173–4
 ivermectin effect pharynx, 167–8
 P-glycoproteins & ivermectin resistance,
 168–9
 PEPCCK in, 49

Halofantrine, **74**, 70–4

Hemoglobin digestive enzymes in *P. falciparum*,
65, 64–70
 falcilysin, 66
 falcipain, 66, 68–9, 121
 plasmepsin I & II, 15, 65, 67–8

Hexokinase in *S. mansoni*, 37, 39

HGPRT & HGXPRT (*see* purine salvage
 pathways)

Hydrogenase in *T. vaginalis*, 137

Hydrogenosomes, 129, 135–8

Hymenolepis diminuta
 serotonin & location in host, 178
 serotonin & motility, 176
 niclosamide treatment, 51, 180
 praziquantel treatment, 180

Hypoxanthine, **112**, 13

I

Iodotubercidin, adenosine kinase inhibitor in
T. gondii, 114–5

Immucillin, inhibitor of HGXPRT, 20

Ivermectin, **166**, 165–9, 217
 binding to Cl⁻ channels, 165–8
 in nematode pharynx, 167–8
 P-glycoproteins & drug efflux, 168
 synergism with doxycycline against filariasis,
 217
 use against *O. volvulus*, 166

K

Kinetoplast DNA (kDNA), 107–8

L

Leishmania
 cysteine protease, 121–2
 glyceraldehyde 3P dehydrogenase (GAPDH),
 a target, 105–6
 life cycle and transmission, 90–1
 pentostam, action of, 96
 pteridine reductase, 116–7
 treatment with allopurinol, 112–4

Levamisole (*see* tetramisole)

LSD, **42**, 42, 170

M

Malaria (*see Plasmodium*)

Malic enzyme, 21, 48, 50, 133, 136

Mebendazole, **53**, **171**, 21
 effect on malic dehydrogenase in helminths,
 53–4
 effect on microtubules, 172–3
 motility in *F. hepatica*, 178–9

Mefloquine, **74**, 9, 62, 64, 72–4

Melarsen oxide, **95**, **111**, & *T. brucei*,
 94–5
 adenosine transporters, 111–2
 formation of MeIT, **95**, 94–5

Melarsoprol, **94**, 4, 94–5, 99, 107

Mesocestoides corti & PZQ, 209

Methotrexate & DHFR, 81, 116

Methyridine, **160**, 159–60

Metrifonate, **197**
 schistosome cholinesterase, 196–9

Metronidazole, **138**, 143–8
 antiprotist, 138–9, 141–3
 free radicals, 139–41, 147

Microarrays, DNA, 26, 216

Microtubules, 156, 170–2, 191, 206–7

Motility in helminths, 21, 39, 162, 174–176,
 180–3
 behavior in host, 156, 176–9, 199–201

Myristate, **117**, trypanosomes, 117–8

N

Necator americanus, 159, 167

Neuroactive peptides
 flatworms, 180–1
 nematodes, 174–5

Neuromuscular system
 flatworms, 175–6, 180–3
 nematodes, 156–8, 174–5

224 Index

- Niclosamide, **52**, **180**, 51
 anticestode, 180, 209
- Nicotinic acetylcholine receptors
 agonists & antagonists, 157–62
 in *Ascaris* (nAChR_n), 158–9
 subunit composition, 158–9
 in *S. mansoni*, 196–7
- Nifurtimox, **97**, against Chagas' disease, 4, 97–8
- NMR, uses for, 12, 20–2, identify
 action of anthelmintics, 21
 enzyme inhibitors, 15, 27
 metabolic pathways, 21, 135
- Nucleoside phosphotransferase Formycin B
 inhibition, 110, 113–4
- Nucleoside ribohydrolase iminoribitol
 inhibition, 112
- Nucleoside transporters, 111–2
- O**
- O. dentatum* & levamisole, 161–2
- Onchocerca volvulus*, 12, 158, 162, 216
 effect of ivermectin, 166–7
 Wolbachia endobacteria, 216
- Ornithine decarboxylase, 98–101
 eflornithine, 98–100, 219
 rate of enzyme turnover, 100–1
- Oxamniquine,
 antischistosomal, **205**, 205–6
- 11-oxatetradecanoic acid, **117**, 117–8
- P**
- p*-aminobenzoic acid (PABA), **78**, 77–9
- Paramyosin in schistosome tegument, 191
- Pasteur, Louis, 1, 2
- Pasteur effect in *S. mansoni*, 35
- Pentostam, **96**, against *Leishmania*, 96
- Peroxiredoxin, 97, 142–3
- Phosphatidylinositol phospholipase C
 (PIPLC), 194–5, 197, 199
- Phosphoenolpyruvate carboxykinase (PEPCK),
 46, 49, 136
- Phosphofructokinase (ATP-PFK), 7
Ascaris suum, 45
F. hepatica, 40–4
 activation by serotonin, 40–5
S. mansoni, 40–5
 antimonial inhibition, 44–5
 cloning, 45
- Phosphofructokinase (PP_i-PFK)
E. histolytica, 131–2, 143–5
Giardia, 134, 136
Toxoplasma, 144–146
- Piperazine, **164**, antinematodal, 164, 182
- Plasmeprin I & II (*see* proteases)
- Plasmodium falciparum*
 drugs used against, 60–4, 74–6
 antisense oligos, 84–5
 artemisinin, 74–5
 chloroquine action, 61–4
 resistance, 70–6
 protease inhibitors (*see also* proteases)
 fluoromethyl ketones, 69
 of meozoites, 83–4
 oxalic bis. . . , **69**, 68–9
 SC-50883, **67**, 66–7
 Silva's #7, **68**, 67–8
 pyrimethamine & sulfadoxine, 77–82
 resistance, 82–3
 quinine, 60–3, 76
 trimethoprim, 81–2
 genomics, 26–7
 hemoglobin digestion, 63–70
 life cycle, **59**, 58–60
- P. vivax* & *P. ovale*, 9, 58–9
 chloroquine, 61–4,
 halofantrine, 74
 mefloquine, 9, 74
 primaquine & hypnozoites, 76–7
- Polyamines & ODC, 98–101
- Potassium antimony tartrate, **44**
S. mansoni PFK, 44–5, 179, 204
L. donovani, 96
- Praziquantel (PZQ), **180**
 effects on tapeworms, 208–9
 motility of helminths, 180
S. mansoni tegument, 199–205
- Primaquine, **76**, 76–7
- Proteases
 amitochondrial protists, 149–50
 malaria, 15, 20, 64–70, 83–4
 hemoglobin digestion, 64–70
 falcilysin, 66
 falcipain, 66–8, 121
 plasmepsins, 15, 65–8
 merozoite penetration, 83–4
 plasminogen activators, 84
 trypanosomatids (cruzain), 120–2
- Protein farnesyl transferase (PFT) in
 trypanosomes, 119–20
- Protein prenylation, 119
- Proteomics, 28–30
- Purine salvage pathways, **110**
 adenosine kinase
 a target in *T. gondii*, 114–5

- allopurinol inhibition, 13, 112–4
 Formycin B inhibition in *Leishmania*, 110, 113–4
 nucleoside transporters, 111–2
 nucleoside ribohydrolase, 112
 phosphoribosyl transferase (PRT)
 HGXPRT
 P. falciparum, 20, 109
 T. gondii, 109
 hypoxanthine *T. cruzi*, 110
 xanthine *Leishmania*, 109, 114
 Pyrantel, **160**, 159–60,
 Pyrimethamine, **81**, 4, 8, 70, 78–82,
 Pyrimidine metabolism, 108–9, 115–6
 Pyrophosphate analogs
 inhibitors of PPI kinases, 143–4
 multisubstrate inhibitors, 145–6
 tetraisopropyl carbonyl... , **144**–5
 Pyruvate dehydrogenase complex (PDC),
 49–50
 Pyruvate: ferredoxin oxidoreductase (PFOR),
 137–8, 147–8
 E. histolytica, 133, 138
 Giardia, 138, 148
 T. vaginalis, reduction of metronidazole,
 138–41
 Pyruvate kinase (PK), 46, 107
 Pyruvate phosphate dikinase (PPDK), 132,
 145
 Pyruvate transporters *T. brucei*, 104
- Q**
- quinidine, 60–2
 quinine, **60**, 1, 8, 60–2, 64, 74, 76
- R**
- rafoxanide against *F. hepatica*, 178
 rhodoquinone, **53**, 48–9, 52–3
- S**
- Salicylhydroxamic acid, 105
Schistosoma hematobium, 30, 34
 acetylcholinesterase, 196–7
 metrifonate treatment, 197–8
 oxamniquine treatment, 205–6
 PZQ treatment, 199
Schistosoma japonicum, 34, 199, 205
Schistosoma mansoni, 11
 genome, 24–5
 glucose metabolism, 35–9, 194–5
 acetylcholine effect, 196–7
 glucose transporters, 36, 194–5
 phosphofructokinase, 40–5
 cloned, 45
 serotonin effects, 41–4
 life cycle, 34
 motility
 neuromuscular system, 175–6
 neuropeptides, 180–1
 praziquantel effects, 180, 200
 serotonin effects, 176–7
 serotonin uptake, 177
 oxamniquine treatment, 205–6
 praziquantel treatment, 199–205
 Ca²⁺ influx, 204–5
 host immune system, 203–4
 resistance to, 202–4
 tegument
 structure and functions, 189–94
 dyneins, 206–7
 proteins, 192–4
 Serotonin (5-HT), **42**
 agonists and antagonists, 42–3
 cestodes, 176–7, 178–9
 nematodes, 169–70
 platyhelminths, 176–7, increases
 cAMP, 42
 glycolysis, 40–3
 motility, 21, 42, 178–9
 PFK activity, 41–3
 receptors, 43–4, 169–70, 176, 183,
 signal transduction, 43–4
 Screening for drugs, 2, 8–11, 66–8, 82, 146, 199
 Signal transduction, 41–4, 169–70
 Sodium stibogluconate (*see* Pentostam)
 Stibophen, **44**, 44–5
 Sulfadoxine, **78**, 70, 77–82
 Sulfonamides, 4, 5, 7, 12, 77–82
 Superoxide dismutase (Fe-SOD), 142–3
 Suramin, **106**, 106–7
 Sutherland, Earl, 42
- T**
- Tetrahydrofolate, **81**, 77, 79–81, 116
 Tetramisole (levamisole), **52**, **160**, 21
 nicotinic receptors, 158–60
 fumarate reductase, 51–2
 resistance to, 160–3, 182
 Thiabendazole, **171**
 antimicrotubule anthelmintic, 173
 Thiolactomycin, 118
 5-thio-D-glucose, **39**, 39
 Tinidazole, **138**, 138–9
 Topoisomerases, *T. brucei*, 107–8, 216

226 Index

- Toxoplasma gondii*, 10, 111, 114–6, 118–9, 144–6, 216
 DNA microarrays, 216
 PP_i analogs against, 144–6
- Trichomonas vaginalis*
 biology, 131
 hydrogenase, 137
 hydrogenosomes, 135–7
 metronidazole effect, 138–9, 141
 PFOR, 137, 148, 219
 proteinases as targets, 149–50
- Triclabendazole (TCBZ), **207**, 207–8
- Trimethoprim, **81**, 81–2
- Triose phosphate isomerase, 193
- Trypanosoma brucei*, 90, 92
 glycosomes, 101–6
 suramin effect on, 106–7
 ODC turnover rate, 98, 99–101
 pyruvate transporters, 104–5
 topoisomerase II, 216
 tryparedoxin, 97, 217–8
 tryparedoxin peroxidase, 217–8
 VSGs, 117–9, 194
- T. cruzi* (*Chagas' disease*), 10, 25, 90
 aerobic glycolysis, 105–6
 allopurinol treatment, 112–3
 cruzain, 120–1
 glyceraldehyde PDH, 105–6
 nifurtimox against, 94, 97–8
 PRTs, 109–10, 117
 trypanothione reductase, 93
- Trypanosomatids, 19
 genomics, 25
 life cycles and transmission, 90–1
 polyamines & ODC, 97–101
 Trypanothione synthesis, 93–4
 Trypanothione reductase, 19, 92
 antimonial inhibition, 96
 arsenical inhibition, 94–5, 107
 role in virulence, 92
- Tryparedoxin, 97, 217–8
- V**
- Variant surface glycoproteins, 16, 104
 GPI anchor, 117
 inhibition by (O-11), **117**, 117–8
- Verapamil, 71
- W**
- Wuchereria bancrofti*, 1, 12, 22
 diethylcarbamazine against microfilariae, 162
- Wolbachia endobacteria, 216–7
- Woods, D. D., 78–9
- X**
- xanthine PRT in *Leishmania*, 109–10, 114